Idera Pharmaceuticals, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Idera Pharmaceuticals, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Idera Pharmaceuticals, Inc.. The Company's principal activity is discovering and developing novel therapeutics that modulate immune responses through Toll-like Receptors (TLR). TLRs are specific receptors present in immune system cells that direct the immune system to respond to potential disease threats. The Company discovers and develops synthetic DNA- and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies and for use as vaccine adjuvants. It has three internal programs, in oncology, infectious diseases, and autoimmune diseases and two collaborative alliances relating to the development of treatments for asthma and allergies and the development of adjuvants for vaccines. The Company is currently conducting a Phase 2 trial of IMO-2055 in oncology and a Phase 1/2 trial of IMO-2055 in combination with chemotherapy in oncology. Its trademarks are IMOtm, Idera(R), IMOxine(R) and GEM(R). The Company operates in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report